DMAAR
Drugs Made In America Acquisition Corp. RightsNASDAQ
Key Statistics
Market Cap
$1.83M
P/E Ratio
—
EPS
—
Beta
—
52W High
$0.24
52W Low
$0.04
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Drugs Made In America Acquisition Corp. Rights
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC) dedicated to merging with innovative pharmaceutical enterprises in the U.S. With a strategic focus on enhancing domestic drug manufacturing capabilities, DMAAR aims to address rising healthcare demands and alleviate supply chain challenges. Leveraging a highly experienced management team, the company seeks to unlock significant growth opportunities within the pharmaceutical sector while delivering sustainable returns to its investors and fostering a revitalized American healthcare landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1.46% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.21 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $20.40M |
| Float | $27.31M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
117.54%
HV 20-Day
174.79%
HV 30-Day
164.61%
HV 60-Day
175.59%
HV Rank
87.7%
Volatility is currently contracting
Data last updated: 5/25/2026